Index microvascular resistance (IMR) in heart transplant patients (IMR-HT study): Study protocol.

<h4>Background</h4>Acute allograft rejection (AAR) is an important cause of morbi mortality in heart transplant (HT) patients, particularly during the first year. Endomyocardial biopsy (EMB) is the "gold standard" to guide post- heart transplantation treatment. However, it is a...

Full description

Saved in:
Bibliographic Details
Main Authors: Ainhoa Pérez-Guerrero, Jean Paul Vilchez-Tschischke, Luis Almenar Bonet, Jose Luis Diez Gil, Teresa Blasco Peiró, Salvatore Brugaletta, Josep Gomez-Lara, José González Costello, Paula Antuña, Vanesa Alonso Fernández, Fernando Sarnago Cebada, María Dolores García-Cosio, Francisco Hidalgo Lesmes, Amador López Granados, Ramón López-Palop, Iris Paula Garrido, Rosa María Cardenal Piris, Diego Rangel Sousa, Georgina Fuertes Ferre
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0315053
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849717069077020672
author Ainhoa Pérez-Guerrero
Jean Paul Vilchez-Tschischke
Luis Almenar Bonet
Jose Luis Diez Gil
Teresa Blasco Peiró
Salvatore Brugaletta
Josep Gomez-Lara
José González Costello
Paula Antuña
Vanesa Alonso Fernández
Fernando Sarnago Cebada
María Dolores García-Cosio
Francisco Hidalgo Lesmes
Amador López Granados
Ramón López-Palop
Iris Paula Garrido
Rosa María Cardenal Piris
Diego Rangel Sousa
Georgina Fuertes Ferre
author_facet Ainhoa Pérez-Guerrero
Jean Paul Vilchez-Tschischke
Luis Almenar Bonet
Jose Luis Diez Gil
Teresa Blasco Peiró
Salvatore Brugaletta
Josep Gomez-Lara
José González Costello
Paula Antuña
Vanesa Alonso Fernández
Fernando Sarnago Cebada
María Dolores García-Cosio
Francisco Hidalgo Lesmes
Amador López Granados
Ramón López-Palop
Iris Paula Garrido
Rosa María Cardenal Piris
Diego Rangel Sousa
Georgina Fuertes Ferre
author_sort Ainhoa Pérez-Guerrero
collection DOAJ
description <h4>Background</h4>Acute allograft rejection (AAR) is an important cause of morbi mortality in heart transplant (HT) patients, particularly during the first year. Endomyocardial biopsy (EMB) is the "gold standard" to guide post- heart transplantation treatment. However, it is associated with complications that can be potentially serious. The index of microvascular resistance (IMR) is a specific physiological parameter used to assess microvascular function. Invasive coronary assessment has been shown to be both feasible and safe. Detection of coronary microvascular dysfunction (MCD) by IMR may help to identify high risk HT patients. In fact, an increased IMR measured early after HT has been associated with AAR, higher all-cause mortality and adverse cardiac events. A high IMR value early after HT may identify patients at higher risk who require increased surveillance or adjustments in immunosuppressive therapy. Conversely, a low IMR value may support reducing the number of EMBs. Our aim is to evaluate IMR in heart transplant patients within the first year. Changes in management after knowing IMR values and prognostic implications of IMR in a long term follow up will also be assessed.<h4>Study design</h4>The IMR-HT study (NCT06656065) is a multicenter, prospective study that will include post-HT consecutive stable patients undergoing coronary physiological assessment in the first three months and one year. Cardiac adverse events will be evaluated at one year for up to five years. A clinical management algorithm is proposed: after knowing IMR values the physician will be able to reduce the number of biopsies established in each center protocol or modify immunosuppression therapy.<h4>Conclusions</h4>IMR values may vary within the first year after heart transplant. IMR assessment will be useful to identify high risk heart transplant patients, leading to possible changes in management and prognosis.
format Article
id doaj-art-1a55d0719fb849ab884366a8cf488b08
institution DOAJ
issn 1932-6203
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-1a55d0719fb849ab884366a8cf488b082025-08-20T03:12:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01205e031505310.1371/journal.pone.0315053Index microvascular resistance (IMR) in heart transplant patients (IMR-HT study): Study protocol.Ainhoa Pérez-GuerreroJean Paul Vilchez-TschischkeLuis Almenar BonetJose Luis Diez GilTeresa Blasco PeiróSalvatore BrugalettaJosep Gomez-LaraJosé González CostelloPaula AntuñaVanesa Alonso FernándezFernando Sarnago CebadaMaría Dolores García-CosioFrancisco Hidalgo LesmesAmador López GranadosRamón López-PalopIris Paula GarridoRosa María Cardenal PirisDiego Rangel SousaGeorgina Fuertes Ferre<h4>Background</h4>Acute allograft rejection (AAR) is an important cause of morbi mortality in heart transplant (HT) patients, particularly during the first year. Endomyocardial biopsy (EMB) is the "gold standard" to guide post- heart transplantation treatment. However, it is associated with complications that can be potentially serious. The index of microvascular resistance (IMR) is a specific physiological parameter used to assess microvascular function. Invasive coronary assessment has been shown to be both feasible and safe. Detection of coronary microvascular dysfunction (MCD) by IMR may help to identify high risk HT patients. In fact, an increased IMR measured early after HT has been associated with AAR, higher all-cause mortality and adverse cardiac events. A high IMR value early after HT may identify patients at higher risk who require increased surveillance or adjustments in immunosuppressive therapy. Conversely, a low IMR value may support reducing the number of EMBs. Our aim is to evaluate IMR in heart transplant patients within the first year. Changes in management after knowing IMR values and prognostic implications of IMR in a long term follow up will also be assessed.<h4>Study design</h4>The IMR-HT study (NCT06656065) is a multicenter, prospective study that will include post-HT consecutive stable patients undergoing coronary physiological assessment in the first three months and one year. Cardiac adverse events will be evaluated at one year for up to five years. A clinical management algorithm is proposed: after knowing IMR values the physician will be able to reduce the number of biopsies established in each center protocol or modify immunosuppression therapy.<h4>Conclusions</h4>IMR values may vary within the first year after heart transplant. IMR assessment will be useful to identify high risk heart transplant patients, leading to possible changes in management and prognosis.https://doi.org/10.1371/journal.pone.0315053
spellingShingle Ainhoa Pérez-Guerrero
Jean Paul Vilchez-Tschischke
Luis Almenar Bonet
Jose Luis Diez Gil
Teresa Blasco Peiró
Salvatore Brugaletta
Josep Gomez-Lara
José González Costello
Paula Antuña
Vanesa Alonso Fernández
Fernando Sarnago Cebada
María Dolores García-Cosio
Francisco Hidalgo Lesmes
Amador López Granados
Ramón López-Palop
Iris Paula Garrido
Rosa María Cardenal Piris
Diego Rangel Sousa
Georgina Fuertes Ferre
Index microvascular resistance (IMR) in heart transplant patients (IMR-HT study): Study protocol.
PLoS ONE
title Index microvascular resistance (IMR) in heart transplant patients (IMR-HT study): Study protocol.
title_full Index microvascular resistance (IMR) in heart transplant patients (IMR-HT study): Study protocol.
title_fullStr Index microvascular resistance (IMR) in heart transplant patients (IMR-HT study): Study protocol.
title_full_unstemmed Index microvascular resistance (IMR) in heart transplant patients (IMR-HT study): Study protocol.
title_short Index microvascular resistance (IMR) in heart transplant patients (IMR-HT study): Study protocol.
title_sort index microvascular resistance imr in heart transplant patients imr ht study study protocol
url https://doi.org/10.1371/journal.pone.0315053
work_keys_str_mv AT ainhoaperezguerrero indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT jeanpaulvilcheztschischke indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT luisalmenarbonet indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT joseluisdiezgil indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT teresablascopeiro indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT salvatorebrugaletta indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT josepgomezlara indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT josegonzalezcostello indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT paulaantuna indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT vanesaalonsofernandez indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT fernandosarnagocebada indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT mariadoloresgarciacosio indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT franciscohidalgolesmes indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT amadorlopezgranados indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT ramonlopezpalop indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT irispaulagarrido indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT rosamariacardenalpiris indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT diegorangelsousa indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol
AT georginafuertesferre indexmicrovascularresistanceimrinhearttransplantpatientsimrhtstudystudyprotocol